10-Nov-2025 6:52 AM CST - Yahoo Finance Editas: Q3 Earnings Snapshot Editas Medicine Inc. EDIT) on Monday reported a loss of $25.1 million in its third quarter.
29-Sep-2025 12:14 AM CST - Yahoo Finance Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a "Buy" rating on the stock and a $5 price target. The positive stance follows the nomination of EDIT-401 as the company's lead Vivo program.
2-Sep-2025 5:22 AM CST - Yahoo Finance Can Editas Medicine (NASDAQ:EDIT) Afford To Invest In Growth? Given this risk, we thought we'd take a look at whether Editas Medicine (NASDAQ:EDIT) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow).
12-Aug-2025 5:42 PM CST - Yahoo Finance Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
12-Aug-2025 3:25 PM CST - Yahoo Finance Editas: Q2 Earnings Snapshot Editas Medicine Inc. EDIT) on Tuesday reported a loss of $53.2 million in its second quarter.
28-Jun-2025 4:04 AM CST - The Motley Fool Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per share in the next year. From recent prices, this implies a gain of about 53% over the next 12 months.
10-Nov-2025 6:52 AM CST - Yahoo Finance Editas: Q3 Earnings Snapshot Editas Medicine Inc. EDIT) on Monday reported a loss of $25.1 million in its third quarter.
29-Sep-2025 12:14 AM CST - Yahoo Finance Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a "Buy" rating on the stock and a $5 price target. The positive stance follows the nomination of EDIT-401 as the company's lead Vivo program.
2-Sep-2025 5:22 AM CST - Yahoo Finance Can Editas Medicine (NASDAQ:EDIT) Afford To Invest In Growth? Given this risk, we thought we'd take a look at whether Editas Medicine (NASDAQ:EDIT) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow).
12-Aug-2025 5:42 PM CST - Yahoo Finance Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
12-Aug-2025 3:25 PM CST - Yahoo Finance Editas: Q2 Earnings Snapshot Editas Medicine Inc. EDIT) on Tuesday reported a loss of $53.2 million in its second quarter.
28-Jun-2025 4:04 AM CST - The Motley Fool Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per share in the next year. From recent prices, this implies a gain of about 53% over the next 12 months.
